USAID's Global Tuberculosis Program




Expanding the DOTS Strategy Through Partnerships and Capacity Building

World TB Day, National Press Club, March 24, 2003



USAID Health Programs by Primary Funding Category

Total Funding: \$1.56 Billion (FY 2002)





Why is USAID working on TB?

- Significant development/economic implications
 - 2-3 million deaths each year
 - 98% of deaths occur in developing world
 - Affects the economically productive population
- Serious global public health threat
 - 1/3 of the world's population is infected.
 - 8 million new cases per year
 - Each person with active TB can infect 10-15 people/year
- Key factor in survival of people living with HIV/AIDS
 - 1/3 of AIDS patients die of TB
- Implications for women's health
 - 750,000 women of reproductive age die of TB each year



Status of TB Control

- 148 of 210 countries are implementing DOTS
- 80% treatment success with DOTS (SS+)
- 28% treatment success with non-DOTS (SS+)
- 55% of population "covered" by DOTS
- 60% of estimated SS+ cases globally were undetected (2000)
- Vietnam was the only HBC to achieve targets for case detection and cure (2000)



Challenges to TB Control

- Lack of adequately trained workforce and cadre of international TB experts
- HIV co-infection and drug resistance
- Need for secure drug supplies for ALL infectious patients
- Insufficient technology for diagnosing and managing TB
- Limited cooperation with private providers




USAID's Goal and Objective

Goal: To contribute to the global reduction of morbidity and mortality associated with Tuberculosis.

Objective: Enhance country capacity to prevent and cure Tuberculosis and achieve global targets of 70% case detection and 85% treatment success rates.



USAID TB Funding Timeline





USAID's Expanded Response: What We Will Do

- Expand and strengthen DOTS
- Increase and strengthen human resource capacity
- Develop and disseminate new tools and approaches
- Adapt DOTS to address special challenges
 - HIV/AIDS TB co-infection
 - TB drug resistance



USAID's Expanded Response: How We Will Do It

- Focus on country level
- Expand partnerships
- Build capacity of our partners
- Build capacity of USAID
- Communication and advocacy




Selection Criteria for TB Country Programs

- Countries of greatest need as defined by:
 - Greatest burden of TB/high incidence of TB (case detection estimated rates over 100/100,000)
 - Significantly contribute to the global burden of TB
 - High HIV/AIDS prevalence
 - Potential of escalating multi-drug resistance
- Technical & managerial feasibility
- Political commitment




Where Is USAID Working?



TB Funding By Region (FY 2002)

Total: \$77,945,000





Expand and Strengthen DOTS

- Laboratory renovation and equipment
- Preparation of national plans for DOTS expansion
- Development and dissemination of norms and guidelines
- Technical assistance for procurement and management of TB drugs
- Program monitoring and supervision
- Training of health personnel
- Standardize and improve information systems



Increase and Strengthen Human Resource Capacity

- Train health personnel at all levels doctors, nurses, lab technicians, community health workers
- Develop and disseminate training materials
- Support preparation of national plans for human resource development
- Expand pool of TB consultants



Develop and Disseminate New Tools and Approaches

- Clinical trials new treatment regimens, FDCs
- Diagnostics rapid, affordable and functional;
 IC test strip
- Operations research
 - To improve access and quality
 - Community based approaches
 - Public/private mix
 - Social, economic and behavior research
 - Role of incentives
 - Cost effectiveness of approaches to manage MDR TB



Adapt DOTS to Address Special Challenges (HIV/AIDS-TB and TB Drug Resistance)

- Epidemiological analysis and modeling
- Promote VCT; link to TB and HIV/AIDS services
- Strengthen TB and HIV/AIDS program coordination
- Test new service delivery approaches
- DOTS Plus for MDR TB pilot projects
- TB drug resistance surveys
- Lab strengthening to monitor resistance



USAID's Role in TB Drug Management

- Expertise in improving pharmaceutical management systems
- Drug management now recognized as a critical factor in DOTS expansion
- TA to Stop TB and GDF in drug management issues, including:
 - Drug management assessments in 15 countries
 - TB/Drug management workshops and training



Key Partners

- Host-country National TB Programs
- Stop TB Partnership
- TB Coalition for Technical Assistance (TBCTA)
- WHO/Geneva and Regional Offices
- CDC and NIH
- CSH Grants Program

- IUATLD
- GFATM
- Global TB Drug Facility
- NGOs/PVOs
- RPM Plus
- Other Donors



STOP TB Partnership: USAID's Role

- A leading partner in development of Stop TB Partnership
- Catalyst in development of Global Plan
- Member of Stop TB Coordinating Board
- Member of technical working groups
- Direct support to the Stop TB Secretariat
- Influential in launch of Global TB Drug Facility





